Share This Page
Drug Price Trends for NDC 58151-0078
✉ Email this page to a colleague
Average Pharmacy Cost for 58151-0078
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARDURA XL 4 MG TABLET | 58151-0078-93 | 6.64200 | EACH | 2025-11-19 |
| CARDURA XL 4 MG TABLET | 58151-0078-93 | 6.64147 | EACH | 2025-09-17 |
| CARDURA XL 4 MG TABLET | 58151-0078-93 | 6.64878 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58151-0078
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 58151-0078
Introduction
The pharmaceutical landscape for NDC 58151-0078, a specific drug identifier within the National Drug Code (NDC) system, requires comprehensive evaluation to understand current market dynamics, competitive positioning, regulatory considerations, and future pricing trends. This analysis aims to provide pharmaceutical manufacturers, investors, healthcare providers, and policy-makers with strategic insights into the product’s market viability and price trajectory.
Product Overview and Therapeutic Context
NDC 58151-0078 corresponds to [Insert specific drug name here], which is indicated for [insert primary indication]. Its formulation, mechanism of action, and clinical efficacy have positioned it within [insert relevant therapeutic class]. The drug has demonstrated benefits in [list key clinical advantages], contributing to its adoption in [hospital, outpatient, specialty care, etc.].
Understanding the drug’s therapeutic niche, along with existing treatment protocols, informs the competitive landscape and pricing strategies. The scarcity or abundance of alternative therapies influences market penetration and reimbursement potential.
Regulatory Status and Market Entry
The regulatory status is crucial in assessing market access trajectory. The drug has obtained [FDA approval/market authorization], with certain restrictions or indications, which directly impacts launch timelines and pricing flexibility. Patent protections or exclusivities, such as orphan drug designation or data exclusivity, can shield against generic or biosimilar competition, affecting price sustainability.
In regions outside the U.S., like the EU or Asia, varying regulatory pathways may influence timing and cost structures. The presence or absence of recent exclusivity clauses heavily impacts projected price windows and revenue potential.
Current Market Landscape
Market Size and Segmentation
The total addressable market (TAM) for NDC 58151-0078 is driven by [prevalence rates, disease incidence, and diagnosis rates]. For example, assuming a [specific prevalence] among U.S. adults, with an estimated [number] diagnosed annually, the potential patient population under treatment is substantial. Segmentation includes:
- Hospital vs. outpatient administration
- Reimbursement environment
- Pricing tiers for specialty vs. primary care
Competitive Environment
Key competitors include [list of direct competitors or alternative therapies]. Their market share, pricing, and clinical outcomes define the competitive pressure on NDC 58151-0078. The entry of biosimilars or generics could significantly influence price erosion over time.
Market Penetration and Adoption
Early adoption rates, driven by [clinical guidelines, formulary inclusion, physician familiarity], suggest how swiftly the drug is integrated into standard practice. Payer coverage policies and patient affordability substantially impact market share growth and revenue projections.
Pricing Strategies and Trends
Current Pricing Landscape
The existing list price for NDC 58151-0078 in the U.S. ranges from $[insert dollar range], depending on dosage form, strength, and packaging. Reimbursement structures, including Medicare, Medicaid, and private insurers, influence net prices and access.
Factors Affecting Price Points
- Regulatory exclusivity periods often sustain premium pricing until patent expiration or biosimilar entry.
- R&D and manufacturing costs, especially if the drug involves complex biologic processes, support higher price points.
- Market competition and the availability of substitutes exert downward pressure.
- Reimbursement negotiations and value-based pricing models focus on clinical benefit and overall cost savings, shaping future price trajectories.
Projection of Price Trends
Considering industry trends, the typical lifespan of exclusivity (often 12-14 years in biologics, shorter in small molecules), and competitive threats, prices are expected to:
- Remain relatively stable during patent protection periods.
- Experience gradual erosion post-patent expiry due to biosimilar or generic competition.
- Be influenced by value-based agreements emphasizing outcomes and total cost of care.
In the next 5 years, prices may decline by [percentage] following patent expiration, with potential revisions driven by market demand and healthcare policy reforms.
Market Entry and Future Price Projections
Scenario 1: Continued Market Exclusivity
If NDC 58151-0078 maintains patent protection and exclusivity, prices could remain near current levels, particularly if clinical benefits justify premium pricing. Manufacturers can leverage brand loyalty and formulary support to sustain revenues.
Scenario 2: Entry of Biosimilars or Generics
Biosimilar competition could initiate price reductions of 20-40% within two years of launch, significantly expanding patient access but compressing profit margins. Price erosion accelerates with multiple entrants.
Scenario 3: Policy and Reimbursement Changes
Healthcare reforms emphasizing value-based care could influence price ceilings and lead to increased negotiations, potentially capping future prices based on demonstrated clinical and economic value.
Market Growth Drivers and Risks
Drivers
- Expansion into newly approved indications.
- Increased disease awareness and screening.
- Payers' willingness to reimburse for innovative therapies.
- Strategic alliances or expansion into international markets.
Risks
- Patent challenges or litigation.
- Entry of lower-cost alternatives.
- Regulatory hurdles delaying market expansion.
- Changes in healthcare policy affecting reimbursement.
Key Takeaways
- NDC 58151-0078 operates within a competitive and evolving therapeutic landscape, with market size driven by disease prevalence and treatment standards.
- Current pricing is influenced by clinical value, patent protections, manufacturing complexity, and payer negotiations.
- Price projections must consider patent lifespan, competitive entries, and policy influences.
- Post-patent expiration, expect significant price erosion, but strategic brand positioning may sustain premium pricing longer.
- Continuous market monitoring, including key regulatory changes, competitor activity, and payer policies, remains essential for accurate forecasting.
FAQs
1. What is the primary therapeutic indication for NDC 58151-0078?
It is indicated for [specific condition], targeting [patient population] and utilized within [clinical settings] to improve [clinical outcomes].
2. How does patent protection impact the drug’s pricing?
Patent protection prolongs market exclusivity, allowing manufacturers to set higher prices without generic or biosimilar competition. Once expired, prices tend to decline due to generic entry.
3. What factors could accelerate price reduction post-approval?
The entry of biosimilars or generics, policy changes promoting biosimilar adoption, and payer pressure for discounts significantly accelerate price erosion.
4. How do reimbursement policies influence future prices?
Reimbursement frameworks favoring value-based outcomes may lead to negotiated prices aligned with demonstrated clinical benefits, influencing overall revenue and pricing structure.
5. What is the outlook for international markets?
Global markets may exhibit different pricing dynamics based on regulatory approval timelines, market sizes, and local healthcare reimbursement systems, often leading to lower prices outside the U.S.
References
- [Insert relevant sources, e.g., FDA filings, industry reports, market research databases].
More… ↓
